The 60-second version of Hemant Surgical Industries Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹109 Cr | ₹106 Cr | ₹105 Cr | ₹231 Cr | +28.4% |
| EBITDA | ₹13 Cr | ₹14 Cr | ₹12 Cr | ₹27 Cr | +27.1% |
| EBITDA Margin | 11.9% | 13.1% | 11.6% | 11.5% | — |
| PAT (Net Profit) | ₹8 Cr | ₹10 Cr | ₹8 Cr | ₹18 Cr | +33.5% |
| EPS | ₹7.32 | ₹9.85 | ₹7.7 | — | — |
| ROE | 32.7% | 17.9% | 12.7% | 13.2% | — |
| ROCE | 44.6% | 23.4% | 14.5% | 19.5% | — |
| Total Debt | ₹7 Cr | ₹7 Cr | ₹31 Cr | ₹50 Cr | +91.1% |
| Free Cash Flow | ₹2 Cr | -₹13 Cr | -₹33 Cr | -₹41 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| CIPLA LTD | 31.8x | 9.8% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| APOLLO HOSPITALS ENTER. L | 54.3x | 22.0% |
A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you. 5 high-severity red flags sit above this conclusion and should be read first.